Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 54
Filter
1.
Article in Chinese | WPRIM | ID: wpr-880135

ABSTRACT

OBJECTIVE@#To observe the clinical efficacy of allogeneic peripheral blood stem cell transplantation(allo-HSCT) on the treatment of adult acute leukemia patients, moreover, to establish and evaluate a Logistic model to predict the risk of relapse in adult acute leukemia patients after allo-HSCT.@*METHODS@#The clinical data of 145 adult acute leukemia patients treated by peripheral blood stem cell transplantation in the First Affiliated Hospital of Xi'an Jiaotong University from January 2010 to December 2019 was enrolled and analyzed retrospectively. Complications and survival of patients were observed. The relationship between patients' age, diagnosis, leukocyte count at onset, risk stratification, time of diagnosis to transplantation, HCT-CI, minimal residual disease pre-transplantation, donor-recipient sex relationship, HLA match degree, prophylaxis of graft versus host disease(GVHD), donor age, number of transfused mononuclear cells, CD34 positive cells, engraftment time, acute and chronic GVHD, CMV, EBV infection, and hemorrhagic cystitis and recurrence after transplantation were analyzed by logistic regression. Relapse prediction model was established and evaluated according to the results.@*RESULTS@#Among 145 acute leukemia patients, 81 with acute myeloid leukemia, 64 with acute lymphocytic leukemia, 18 with EBV infection, 2 with post-transplant lymphoproliferative disorder(PTLD), 85 with CMV, 26 with hemorrhagic cystitis, 65 patients developed acute GVHD, 51 patients developed chronic GVHD and 45 patients relapsed. The overall survival (OS) rates in one and three years were 86.4% and 61.8%, and the progress-free survival (PFS) rates in one and three years were 67.5% and 62.4%, respectively. There were significant differences in OS and PFS between relapsed and non-relapsed patients, as well as AML and ALL patients. Univariate analysis revealed that patient's age, risk stratification, time to transplantation, HCT-CI index, ATG based GVHD prophylaxis, minimal residual disease pre-transplantation, GVHD prophylaxis, and acute and chronic GVHD were associated with the relapse of disease, multivariate logistic regression analysis showed that pre-transplantation minimal residual disease showed positively correlation with relapse of the disease, while chronic GVHD showed negatively correlation.@*CONCLUSION@#The relapse rate of adult acute leukemia patients treated with allo-HSCT in our hospital is 31.0%, and OS of AML patients is better than ALL patients'. OS of relapsed patients is significantly lower than non-relapsed patients'. Pre-transplantation minimal residual disease is a risk factor of relapse. The risk of relapse is reduced in patients with chronic GVHD.


Subject(s)
Adult , Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Humans , Leukemia, Myeloid, Acute/therapy , Peripheral Blood Stem Cell Transplantation , Recurrence , Retrospective Studies , Transplantation Conditioning
2.
Article in Chinese | WPRIM | ID: wpr-879845

ABSTRACT

OBJECTIVE@#To study the clinical features and prognosis of childhood acute myeloid leukemia with myelodysplasia-related changes (AML-MRC).@*METHODS@#A retrospective analysis was performed on the medical data of 14 children who were diagnosed with AML-MRC from June 2014 to March 2020, including clinical features, laboratory examination results, and prognosis.@*RESULTS@#Among the 14 children with AML-MRC, there were 9 boys and 5 girls, with a median age of 11 years (range: 1-17 years), a median leukocyte count of 8.3×10@*CONCLUSIONS@#Childhood AML-MRC is often observed in boys, and AML-M5 is the most common type based on FAB classification. Such children tend to have a poor prognosis. HSCT is expected to improve the poor prognosis of children with AML-MRC. However due to the small number of cases, it is necessary to increase the number of cases for further observation.


Subject(s)
Adolescent , Child , Child, Preschool , Female , Hematopoietic Stem Cell Transplantation , Humans , Infant , Leukemia, Myeloid, Acute/therapy , Male , Myelodysplastic Syndromes/therapy , Prognosis , Retrospective Studies
3.
Frontiers of Medicine ; (4): 701-710, 2020.
Article in English | WPRIM | ID: wpr-880968

ABSTRACT

Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cell tumors, prompting scientists and doctors to exploit this strategy to treat other tumor types. Acute myeloid leukemia (AML) is a group of heterogeneous myeloid malignancies. Relapse remains the main cause of treatment failure, especially for patients with intermediate or high risk stratification. Allogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemia effect, which unfortunately puts the patient at risk of serious complications, such as graft-versus-host disease. Although the identification of an ideal target antigen for AML is challenging, CAR T therapy remains a highly promising strategy for AML patients, particularly for those who are ineligible to receive a transplantation or have positive minimal residual disease. In this review, we focus on the most recent and promising advances in CAR T therapies for AML.


Subject(s)
Hematopoietic Stem Cell Transplantation , Humans , Immunotherapy, Adoptive , Leukemia, Myeloid, Acute/therapy , Receptors, Chimeric Antigen , T-Lymphocytes
4.
Journal of Experimental Hematology ; (6): 2089-2092, 2020.
Article in Chinese | WPRIM | ID: wpr-880020

ABSTRACT

Acute myeloid leukemia (AML) is a malignant tumor with abnormal myelocyte differentiation. With the development of immunological technology, great importance has been attached to the immunotherapy of AML patients, which may become an effective treatment strategy for AML, and providing a new means for the prognosis and survival. In this review, the advanced research of immunotherapy for AML, such as antibody-dependent drugs, chimeric antigen receptor T cell therapy, and checkpoint inhibitors, the bastest reaserch advanves of clinical experiment for immunotherapy was summarized briefly.


Subject(s)
Humans , Immunologic Factors , Immunotherapy , Immunotherapy, Adoptive , Leukemia, Myeloid, Acute/therapy , T-Lymphocytes
5.
Rev. chil. obstet. ginecol. (En línea) ; 84(4): 332-336, 2019. graf, ilus
Article in Spanish | LILACS | ID: biblio-1058156

ABSTRACT

RESUMEN Introducción y objetivos: El sarcoma mieloide puede ser la primera manifestación de la leucemia mieloide aguda (LMA), presentarse simultáneamente o constituir una forma de recaída. Material y métodos: Presentamos el caso de una paciente con sarcoma mieloide uterino, como forma de recaída de LMA. Resultados: El diagnóstico se basa en los hallazgos histopatológicos, la inmunohistoquímica y el inmunofenotipo. El tratamiento y el pronóstico son similares a LMA. Conclusión: La afectación uterina por leucemia mieloide extramedular es rara pero debe tenerse en cuenta en el diagnostico diferencial de una masa uterina en aquellas pacientes con antecedentes de LMA.


ABSTRACT Introduction and objectives: Myeloid Sarcoma can present as a first MLA sign, concurrently with or at relapse form. Materials and methods: We present the case of a patient with uterine myeloid sarcoma, as a form of relapse of MLA. Results: The diagnostic is based on the histopathology findings along with immunohistochemistry and immunophenotyping. Conclusion: Uterine involvement due to extramedullary myeloid leukemia is rare but it should be taken into account in the differential diagnosis of a uterine mass in those patients with a history of MLA.


Subject(s)
Humans , Female , Aged , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/therapy , Sarcoma, Myeloid/diagnostic imaging , Thrombosis , Immunohistochemistry , Magnetic Resonance Spectroscopy , Leukemia, Myeloid, Acute/pathology
7.
Ciênc. Saúde Colet ; 23(2): 399-408, Fev. 2018. tab
Article in Portuguese | LILACS | ID: biblio-890531

ABSTRACT

Resumo O presente artigo analisa os impactos materiais e imateriais imersos na experiência de adultos jovens com um adoecimento de longa duração - Leucemia Mieloide Aguda. Decorre de pesquisa mais ampla, inspirada na Fenomenologia de Alfred Schutz. Os dados foram obtidos por entrevistas em profundidade com quatro jovens, de 20 a 28 anos, em fase de manutenção no tratamento oncológico, entre novembro de 2013 a janeiro de 2014, em Mato Grosso. Os resultados enfocam aspectos marcantes dos impactos na experiência como o processo de descoberta da enfermidade em que o diagnóstico provocou sentimentos mobilizados por ideias sobre uma doença grave. Seguem-se os impactos na aparência devidos ao tratamento, sobressaindo a queda de cabelo e as estratégias cotidianas de enfrentamento, bem como o aumento ou a perda de peso. Por fim, é marcante o impacto da iminência da morte diante da letalidade da doença e o testemunho da ocorrência em pessoas conhecidas, colocando-a como possibilidade concreta para si, mas também como sobreviventes. Os impactos são os efeitos e as transformações na vida das pessoas e seu entorno e evocam (re) ações, contudo, diluem-se na experiência compondo-a, e não sendo homogênea, sua abordagem privilegia a singularidade inscrita em biografias contextualizadas.


Abstract This article analyzes the tangible and intangible impacts involved in the experience of young adults diagnosed with a long-term illness, namely Acute Myeloid Leukemia. It follows on from broader research, inspired by the Phenomenology of Alfred Schutz. The data were obtained through in-depth interviews with four young adults, aged between 20 and 28, who were in the maintenance phase of cancer treatment between November 2013 and January 2014 in the State of Mato Grosso. The results focus on striking aspects of the impacts of the experience during the process of becoming aware of the illness in which the diagnosis provoked feelings mobilized by ideas regarding a serious illness. This is followed by the impacts on appearance due to the treatment, especially hair loss and day-to-day coping strategies, as well as weight gain or loss. Finally, there is the marked impact of the imminence of death due to the lethality of the disease and the testimony of the occurrence in friends and family, but also for the survivors. The impacts are the effects and transformations in the lives of people and their relations and evoke (re)actions, however, they are diluted in the experience composing it, and not being homogeneous, its approach addresses the singularity encountered in contextualized biographies.


Subject(s)
Humans , Male , Female , Adult , Young Adult , Adaptation, Psychological , Leukemia, Myeloid, Acute/therapy , Alopecia/etiology , Cancer Survivors/psychology , Leukemia, Myeloid, Acute/psychology , Attitude to Death , Family/psychology , Interviews as Topic , Friends/psychology , Alopecia/psychology
8.
Rev. salud pública ; 19(5): 657-663, sep.-oct. 2017. tab, graf
Article in Spanish | LILACS | ID: biblio-962053

ABSTRACT

RESUMEN Objetivo Estimar la razón de costo-efectividad de las pruebas para estratificación del riesgo en pacientes pediátricos con Leucemia Mieloide Aguda (LMA). Métodos Se construyó un árbol de decisión con años de vida ganados como medida de efectividad. Los costos fueron estimados desde la perspectiva del sistema de salud colombiano. En los costos de la estratificación se incluyeron los costos del tratamiento consecuente con ella. Los precios de medicamentos fueron tomados del SISMED 2008 y el valor monetario de los procedimientos se extrajo del manual tarifario del ISS 2001 adicionando el 30 %. Todos los costos se expresaron en pesos colombianos del 2010 y el producto interno per-cápita de ese año fue empleado como umbral de costo efectividad. Se condujeron análisis de sensibilidad univariados y probabilísticos. Resultados La razón de costo-efectividad incremental de las pruebas de estratificación a todos los pacientes, fue de $8 559 944. Los resultados son sensibles a las probabilidades de recaída, supervivencia al trasplante y efectos secundarios. Conclusión Las pruebas para estratificación del riesgo en LMA son costo-efectivas dentro del sistema de salud colombiano.(AU)


ABSTRACT Objective To estimate the cost-effectiveness of risk-stratification tests for the treatment of acute myeloid leukemia (AML) in pediatric patients. Methods A decision-tree model was built using Life Years Gained as a measure of effectiveness. Costs were estimated considering the perspective of the Colombian health system. Stratification costs included treatment costs based on said stratification. Drug prices were taken from SISMED (Drug Price Information System) 2008 and the monetary value of the procedures was extracted from the ISS 2001 rate manual, plus 30%. All costs were expressed in Colombian pesos for 2010 and the gross domestic product per capita of the same year was used as a cost-effective threshold. Univariate and probabilistic sensitivity analyzes were performed. Results Risk stratification tests have an incremental cost-effectiveness ratio of COP 8,559,944. These results are sensitive to changes in probabilities of relapse, transplant survival and side effects. Conclusion Risk stratification tests for AML treatment in pediatric patients are cost-effective in the context of the Colombian health care system.(AU)


Subject(s)
Humans , Leukemia, Myeloid, Acute/therapy , Consolidation Chemotherapy , Transplantation, Homologous , Colombia , Risk Assessment , Cost-Effectiveness Evaluation
9.
Einstein (Säo Paulo) ; 15(3): 355-358, July-Sept. 2017.
Article in English | LILACS | ID: biblio-891404

ABSTRACT

ABSTRACT Acute myeloid leukemia is a hematopoietic stem cell neoplastic disease associated with high morbidity and mortality. The presence of FLT3 internal tandem duplication mutations leads to high rates of relapse and decreased overall survival. Patients with FLT3 internal tandem duplication are normally treated with hematopoietic stem cell transplantation in first complete remission. Nevertheless, the incidence of post-transplant relapse is considerable in this group of patients, and the management of this clinical condition is challenging. The report describes the outcomes of patients with FLT3 internal tandem duplication positive acute myeloid leukemia who relapsed after allogeneic hematopoietic stem cell transplantation and were treated with the combination of re-induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Three cases are described and all patients achieved prolonged complete remission with the combined therapy. The combination of induction chemotherapy followed by donor lymphocyte infusion, and the maintenance with azacitidine and sorafenib can be effective approaches in the treatment of post-hematopoietic stem cell transplant and relapsed FLT3 internal tandem duplication positive acute myeloid leukemia patients. This strategy should be further explored in the context of clinical trials.


RESUMO A leucemia mieloide aguda é uma doença neoplásica de células-tronco hematopoiéticas com alta morbimortalidade. A presença de mutações de duplicação em tandem de FLT3 leva a altas taxas de recorrência e a menor sobrevida global. Os pacientes com duplicação em tandem de FLT3 são normalmente tratados com transplante de células-tronco hematopoiéticas na primeira remissão completa. No entanto, a incidência de recidiva pós-transplante é considerável neste grupo de pacientes, e a conduta, nestes casos, é um desafio. O relato descreve os resultados do tratamento de pacientes com leucemia mieloide aguda positiva e duplicação em tandem de FLT3 que recidivaram depois do transplante alogênico de células-tronco hematopoiéticas e que foram tratados com combinação de quimioterapia de reindução, infusão de linfócitos de doador, sorafenib e azacitidina. São descritos três casos, e todos os pacientes apresentaram remissão completa prolongada com a terapia combinada. A combinação de quimioterapia de indução, seguida de infusão de linfócitos do doador, e a manutenção com azacitidina e sorafenib podem ser abordagens eficazes no tratamento da recorrência pós-transplante em pacientes com leucemia mieloide aguda e duplicação em tandem de FLT3. Essa estratégia deve ser mais explorada no contexto de ensaios clínicos.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Phenylurea Compounds/administration & dosage , Azacitidine/administration & dosage , Leukemia, Myeloid, Acute/therapy , Niacinamide/analogs & derivatives , Lymphocyte Transfusion , fms-Like Tyrosine Kinase 3/genetics , Induction Chemotherapy , Antineoplastic Agents/administration & dosage , Recurrence , Leukemia, Myeloid, Acute/genetics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Treatment Outcome , Niacinamide/administration & dosage , Combined Modality Therapy/methods , Neoplasm Recurrence, Local/therapy
10.
Rev. Assoc. Med. Bras. (1992) ; 62(supl.1): 23-24, Oct. 2016.
Article in English | LILACS | ID: biblio-829560

ABSTRACT

SUMMARY The allogeneic hematopoietic stem cell transplantation (HSCT) can cure intermediate and high-risk acute myeloid leukemia. Even with the development of strategies to reduce HSCT toxicity, this is still a complex treatment with high morbidity and mortality. Knowledge of the graft versus leukemia effect of HSCT has prepared the way for the development of Adoptive Immunotherapy or in vitro expansion of activated lymphocytes without alloreactivity, with subsequent intravenous infusion. The infusion of genetically modified T lymphocytes and haploidentical natural killer cells has been tested as an alternative to HSCT with very interesting results worldwide and in Brazil, as we not only have the technology of in vitro expansion of clinical grade lymphocytes available, but also do it according to the Good Manufacturing Practices that have been determined internationally.


RESUMO O transplante de células-tronco hematopoéticas (TCTH) alogênico é curativo para leucemia mielóide aguda de risco intermediário e alto. Mesmo com o desenvolvimento de estratégias para minorar a toxicidade do TCTH, este ainda é um tratamento complexo com elevada morbi-mortalidade. O conhecimento sobre o efeito enxerto contra leukemia do TCTH pavimentou o caminho para o desenvolvimento da Imunoterapia Adotiva ou expansão in vitro de linfócitos ativados, sem alo-reatividade, com posterior infusão endovenosa. A infusão de Linfócitos T geneticamente modificados e de células Natural Killer haploidenticas tem sido testada como alternativa ao TCTH com resultados bastante interessantes no mundo e no Brazil já que não apenas dominamos a tecnologia de expansão in vitro de linfócitos em grau clínico, como o fazemos segundo as Boas Práticas de Manufatura determinadas internacionalmente.


Subject(s)
Humans , Killer Cells, Natural/immunology , Leukemia, Myeloid, Acute/therapy , Immunotherapy, Adoptive/methods , Brazil , Immunotherapy, Adoptive/trends , Hematopoietic Stem Cell Transplantation/methods , Graft vs Leukemia Effect
11.
Rev. méd. hered ; 26(3): 160-166, jul.-sept.2015. tab, graf
Article in Spanish | LILACS, LIPECS | ID: lil-781612

ABSTRACT

El tratamiento de la Leucemia mieloide aguda (LMA) está basado en administración de quimioterapia (QT), que se asocia a importante toxicidad en quienes la reciben. La elección del régimen de QT se basa en edad, estado general y comorbilidades del paciente, empeorando el pronóstico en los adultos mayores. Objetivo: Comparar la evolución de pacientes menores de 60 años (adultos jóvenes) y de mayores de 60 años (adultos mayores) con LMA que recibieron QT. Material y métodos: Estudio descriptivo, retrospectivo en pacientes admitidos en el Hospital Edgardo Rebagliati entre enero de 1995 y diciembre de 2008. Los criterios de inclusión fueron: Diagnóstico de LMA debut, mayor de 18 años, haber recibido QT según Protocolo del Servicio de Hematología. Fueron excluidos los pacientes con LMA promielocítica y los que fueron sometidos a trasplante de progenitores hematopoyéticos. Se determinó la tasa de remisión completa (RC), tasa de persistencia de enfermedad (PE) post QT, tasa de mortalidad asociada a QT (TM) Y curvas de sobrevida libre de enfermedad (SLE) y sobrevida total (ST). Resultados: Se estudiaron 208 pacientes, 153 fueron adultos jóvenes y 55 adultos mayores, los grupos tuvieron características similares. Las tasas de RC, TM y ST mostraron diferencias estadísticamente significativas a favor del grupo adultos jóvenes, mientras que las tasas de PE y SLE no mostraron diferencias. Conclusiones: Los pacientes adultos mayores que reciben QT tienen peor pronóstico en comparación con los pacientes adultos jóvenes. La decisión de tratamiento con QT debe individualizarse, comparando riesgo - beneficio de la QT en cada caso...


Treatment of acute myeloid leukemia (AML) is based on the administration of chemotherapy (CT), which is associated with significant toxicity. The selection of CT is based on age, general condition and presence of comorbidities in the patient, with poor prognosis associated with advanced age. Objective: to compare the clinical outcomes of patients with AML treated with CT below 60 years of age with that of patients above 60 years of age. Methods: A descriptive, retrospective study was carried-out from January 1995 to December 2008 at Hospital Edgardo Rebagliaiti. lnclusion criteria were age above 18 years and to have received CT based on standard protocols by the hospital. Patients with promyelocytic AML and those in whom abone marrow transplant had been performed were excluded. Complete remission rate (CRR), persistence rate (PR), mortality rates (MR) and disease free survival (DFS) and overall survival (OS) curves were obtained. Results: 208 patients were included; 153 were young adults and 55 were older adults, both groups were comparable. CRR, MR and OS were better in young adults, while PR and OS did not differ by age. Conclusions: Older adult patients on CT had poor prognosis compared to younger patients. The decision on staring CT should be individualized balancing the risks and benefits...


Subject(s)
Humans , Young Adult , Leukemia, Myeloid, Acute , Leukemia, Myeloid, Acute/therapy , Epidemiology, Descriptive , Retrospective Studies
12.
Reviews in Clinical Medicine [RCM]. 2015; 2 (4): 209-211
in English | IMEMR | ID: emr-177653

ABSTRACT

Nucleophosmin 1 is a multifunctional protein that shuttles between nucleus and cytoplasm in some subtypes of acute myeloid leukemias. Mutated Nucleophosmin 1 expresses aberrantly in the cytoplasm of the cell and transports from nucleolus to the cytoplasm. It is diagnosed by immunohistochemical techniques, flow cytometry assay and mutational analysis. The aim of this study is to evaluate the effects of Nucleophosmin 1 mutation on the clinical presentations, prognosis, diagnosis and the treatment of acute myeloid leukemia. Thirteen articles were extracted from PubMed, Google scholar and Scopus in which the Nucleophosmin 1 mutation correlated with gingival hyperplasia, high white blood cell count, lymphadenopathy, high platelet count and other signs and symptoms of myelomonocytic and monocytic acute myeloid leukemias. This mutation is a provisional entity in the classification of acute myeloid leukemia, which influences on the prognosis, clinical course and the treatment of some subtypes of acute myeloid leukemias. Nucleophosmin1 mutation has favorable prognostic value in the absence of other concomitant mutations


Subject(s)
Nuclear Proteins , Mutation , Leukemia, Myeloid, Acute/therapy
13.
Rev. cuba. hematol. inmunol. hemoter ; 29(2): 189-197, abr.-jun. 2013.
Article in Spanish | LILACS | ID: lil-672148

ABSTRACT

Introducción: la leucemia mieloide aguda representa alrededor del 20 por ciento de las leucemias agudas de la niñez con una respuesta al tratamiento y supervivencia menores que la leucemia linfoide aguda. Objetivo: describir los resultados obtenidos con el tratamiento de la leucemia mieloide aguda del niño en algunos centros de Cuba en el período 2000-2008. Métodos: se trataron 46 pacientes con leucemia mieloide aguda, se excluyeron los casos con leucemia promielocítica, diagnosticados a partir del año 2000 en las provincias occidentales, Sancti Spíritus y Villa Clara. Se aplicaron dos esquemas de tratamiento tipo BFM en dos períodos: en el primero (2000 -2003) se incluyeron 27 enfermos y en el segundo (2004-2008), 19. La diferencia fundamental entre los dos períodos consistió en la consolidación que en la segunda etapa fue de ciclos más intensos y cortos. Resultados: predominó el sexo masculino (n = 32) y la mediana de edad fue de 9 años. La remisión inicial fue del 71 por ciento en la primera etapa y 89 por ciento en la segunda. La supervivencia libre de eventos (SLE) en todos los pacientes fue del 40 por ciento a los 5 años y la supervivencia global (SV) fue del 44 por ciento en igual período. En la SLE en las dos etapas se encontraron diferencias significativas siendo mayor en la segunda. En los años comprendidos entre el 2000 y el 2003 la SV a los 5 años fue del 31 porciento, mientras que entre 2004 y 2008 fue del 63 por ciento. No se empleó el trasplante de células progenitoras hematopoyéticas de forma sistemática. Conclusiones: estos resultados muestran un nivel comparable a los alcanzados a internacionalmente, lo que representa un importante logro del Sistema Nacional de Salud de Cuba


Introduction. acute myeloid leukemia represents about 20 percent of all leukemias in childhood with results and survival smaller than in acute lymphoid leukemia. Objectives: to describe the results obtained with the treatment of acute myeloid leukemia in children in some Cuban centers in from 2000 to 2008. Methods: forty-six patients from Western provinces of Cuba including Sancti Spiritus and Villa Clara were treated. The majority of the patients were males. The median age was 9 years old. Two periods of treatment were applied, the first from 2000 to 2003 with 27 patients; and the second from 2004 to 2008 with 19 cases. The difference between the two periods was that in the second one the consolidation had short and intensive cycles. Results: the initial remission was 71 percent in the first period and 89 percent in the second. Free survival was 40 percent in 5 years and the overall survival (OS) was 44 percent, but in the first period the OS was 30,8 percent and in the second it was 63,2 percent. Immunophenotype and cytogenetic and molecular alterations were studied only in 10 children. Hematopoietic transplantation was not performed sytematically. Conclusions: these results show a level comparable to those achieved internationally, representing a major achievement of the Cuban National Health System


Subject(s)
Humans , Male , Female , Child , Leukemia, Myeloid, Acute/epidemiology , Leukemia, Myeloid, Acute/mortality , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/therapy , Disease-Free Survival , Survival Analysis
14.
Campinas; s.n; 04 jan. 2013. 68 p. ilus, tab, graf.
Thesis in Portuguese | LILACS | ID: lil-682556

ABSTRACT

Células dendríticas (DCs) são as principais células apresentadoras de antígeno do sistema imune, capazes de estimular o linfócito T a iniciar resposta imune especifica. Vacinas de DCs vêm sendo utilizadas como forma de tratamento imunoterápico adjuvante para várias neoplasias. Protocolos para geração dessas células têm sido desenvolvidos e o método ideal de produção para uso clínico ainda necessita ser definido. É fundamental a definição de protocolos e reagentes que ofereçam, a partir de células mononucleares do sangue periférico, células dendríticas seguras e funcionais para uso clínico. A suplementação de meios de cultura com soro de origem animal e humano leva á riscos de xenosensibilização e transmissão de doenças. O uso do soro autólogo parece oferecer menos riscos ao paciente, porém a presença de fatores imunossupressores nesse soro poderia interferir na qualidade das DCs produzidas. Vários tipos de meios livres de soro, baseados nas boas práticas de produção - "good manufacture practice" (GMP), têm sido utilizados recentemente e parecem ser uma opção viável. O objetivo desse estudo foi avaliar os resultados da diferenciação, maturação e funcionalidade de DCs de pacientes com LMA, produzidas em meios livres de soro e em meio suplementado com soro autólogo. Concluímos que os meios de cultura livres de soro foram eficientes na produção de DCs para fins imunoterápicos em pacientes com LMA. Em contrapartida, o uso de soro autólogo parece interferir na capacidade funcional das DCs geradas.


Dendritic cells (DCs) are the main antigen-presenting cells of the immune system, capable of stimulating T lymphocytes to initiate specific immune responses. Vaccines based on DCs have been used as a treatment adjuvant immunotherapy for various malignancies. Protocols for generating these cells have been developed and the optimal method of production for clinical use remains to be defined. There is a great interest in the definition of protocols and reagents providing from peripheral blood mononuclear cells, functional and safe dendritic cells for clinical use. Supplementation of culture media with serum from animal and human leads to reactions due the animal proteins and transmission of disease. The use of autologous serum seems to offer less risk to the patient, but the presence of immunosuppressive factors may affect the quality of the DCs produced. Several types of serum-free media, based on "good manufacture practice" (GMP), have been used recently and seem to be a viable option. The aim of this study was to evaluate the results of the differentiation, maturation and function of DCs from AML patients, generated in serum-free media and media supplemented with autologous serum. We concluded that the serum-free media were efficient in the production of DCs for immunotherapy in AML patients. However, the use of autologous serum appears to interfere with the functional capacity of generated DCs.


Subject(s)
Humans , Male , Female , Adult , Dendritic Cells , Immunotherapy , Leukemia, Myeloid, Acute/therapy , Culture Media, Serum-Free
15.
Braz. j. med. biol. res ; 44(7): 660-665, July 2011. ilus, tab
Article in English | LILACS | ID: lil-595706

ABSTRACT

We evaluated the outcome of 227 patients with acute myeloid leukemia during three decades (period 1 - 1980’s, N = 89; period 2 - 1990’s, N = 73; period 3 - 2000’s, N = 65) at a single institution. Major differences between the three groups included a higher median age, rates of multilineage dysplasia and co-morbidities, and a lower rate of clinical manifestations of advanced leukemia in recent years. The proportion of patients who received induction remission chemotherapy was 66, 75, and 85 percent for periods 1, 2, and 3, respectively (P = 0.04). The median survival was 40, 77, and 112 days, and the 5-year overall survival was 7, 13, and 22 percent, respectively (P = 0.01). The median disease-free survival was 266, 278, and 386 days (P = 0.049). Survival expectation for patients with acute myeloid leukemia has substantially improved during this 30-year period, due to a combination of lower tumor burden and a more efficient use of chemotherapy and supportive care.


Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , Humans , Male , Middle Aged , Young Adult , Hospitalization/statistics & numerical data , Leukemia, Myeloid, Acute/therapy , Brazil/epidemiology , Disease-Free Survival , Induction Chemotherapy/methods , Leukemia, Myeloid, Acute/mortality , Leukemia, Myeloid, Acute/pathology , Prognosis , Retrospective Studies , Survival Rate , Treatment Outcome
16.
Salud(i)ciencia (Impresa) ; 18(2): 176-178, mar. 2011.
Article in Spanish | LILACS | ID: lil-610120

ABSTRACT

Presentación de un caso clínico en el que la terapia con dasatinib y la quimioterapia se asociaron con supervivencia a largo plazo en un paciente de 51 años, diagnosticado con mastocitosis sistémica y un mal pronóstico inicial.


Subject(s)
Humans , Male , Middle Aged , Leukemia, Myeloid, Acute/diagnosis , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/therapy , Mastocytosis/complications , Mastocytosis/drug therapy , Mastocytosis/therapy
18.
Gezira Journal of Health Sciences. 2011; 7 (1): 98-102
in English | IMEMR | ID: emr-178320

ABSTRACT

Classically, children with acute leukaemia present with symptoms and signs related to infiltration of the bone marrow by leukaemic cells, such as fever, pallor and fatigue, cutaneous and mucosal bleeding and bone pain. Also anorexia and weight loss. This sis a case of acute myeloid leukaemia [AML] which presented with tongue bleeding and then part of the tongue separated completely from the rest of the tongue and it fell from his mouth, few days later it regenerated to a normal tongue. Few days after regeneration of the right side of the tongue, the same previous scenario occurred in the left side, and then regenerated to normal size. This indicates an unusual presentation of AML.


Subject(s)
Humans , Male , Leukemia, Myeloid, Acute/therapy , Child
20.
Article in English | WPRIM | ID: wpr-221454

ABSTRACT

Natural killer (NK) cells can kill a wide range of cancer cells and are a promising tool for cell therapy of cancer. NK cells cytotoxicity is regulated by a balance between stimulatory and inhibitory signals. Interleukin-2 is known to increase NK cell cytotoxicity. Although many cytokines have been studied in efforts to induce durable NK cell expansions, most reports indicate a rather modest effect and the requirement for additional stimuli. We found that contact with the K562 myeloid leukemia cell line, genetically modified to express a membrane-bound form of interleukin-15 and the ligand for the costimulatory molecule 4-1BB, induced vigorous expansion of NK cells from peripheral blood. Based on these findings, we developed a method for large-scale clinical-grade expansion of NK cells. This method is currently used to expand allogeneic NK cells for infusion in patients with leukemia and solid tumors. We here summarize methods for expansion and activation of NK cells from human peripheral blood mononuclear cells as well as clinical-scale methods to produce NK cells for immunotherapy under Current Good Manufacturing Practices (cGMP) conditions.


Subject(s)
Humans , Immunotherapy , Interleukin-2/pharmacology , Killer Cells, Natural/immunology , Leukemia, Myeloid, Acute/therapy , Neoplasms/immunology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
SELECTION OF CITATIONS
SEARCH DETAIL